Roth Positive on Retrophin's (RTRX) Thiola Licensing Deal; Issues Commentary
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall St futures mixed as investors await payrolls data
- Oil falls for a third straight day after US, Iran conclude talks in Doha
- Dollar eases as yen gains ahead of US payrolls, chipmaker stocks struggle
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
Retrophin (RTRX) Enters Agreement for Thiola Marketing Rights in U.S.; Boosts Outlook
May 29, 2014 4:43 PM EDTRetrophin, Inc. (NASDAQ: RTRX) announced that it has entered into a license agreement with Mission Pharmacal Company, a private company based in San Antonio, Texas, for U.S. marketing rights to Thiola (tiopronin). Financial terms of the agreement were not immediately disclosed.
Thiola® is approved by the U.S. Food and Drug Administration for the treatment of cystinuria, a rare genetic cystine... More
